Please select the option that best describes you:

For an older patient with hormone-sensitive high-volume, high-risk prostate cancer with metastases to bone who developed toxicity with enzalutamide, what other oral AR blocker would you offer?  



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more